EP
HRTX icon

Essential Partners’s Heron Therapeutics HRTX Stock Holding History

Essential Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71K Sell
4,008
-1,032
-20% -$827 ﹤0.01% 2039
2026
Q1 		$4.03K Buy
5,040
+2,840
+129% +$3.29K ﹤0.01% 1685
2025
Q4 		$2.86K Sell
2,200
-6,751
-75% -$8.34K ﹤0.01% 1667
2025
Q3 		$11.3K Buy
8,951
+8,938
+68,754% +$14.2K ﹤0.01% 1118
2025
Q2 		$27 Buy
+13
New +$27 ﹤0.01% 2203

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Essential Partners's HRTX Position: Q2 2026 in Review

Essential Partners reduced its Heron Therapeutics (HRTX) stake by 20% in Q2 2026, selling an estimated $827 and leaving 4,008 shares worth $1.71K. The position accounts for ﹤0.01% of the portfolio, ranked #2039.

Essential Partners first reported a position in HRTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $11.3K in Q3 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Essential Partners held 4,008 shares of Heron Therapeutics worth $1.71K as of Q2 2026.
  • Essential Partners sold 1,032 Heron Therapeutics shares in Q2 2026, an estimated $827.
  • Heron Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2039 holding.
  • Essential Partners first reported a position in Heron Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Heron Therapeutics position peaked at $11.3K in Q3 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.